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Abstract	  
Acetaminophen is a common analgesic and antipyretic. 
Metabolism of acetaminophen and acetaminophen-induced 
liver necrosis are predicted using physiologically-based 
pharmacokinetic (PBPK) modeling. Pharmacokinetic means 
the model determines where the drug is distributed in the 
body over time. Physiologically-based means the anatomy 
and physiology of the human body is reflected in the 
structure and functioning of the model. Acetaminophen is 
usually safe and effective when taken as recommended, but 
consumption at higher levels may lead to liver damage. 
Additionally, other factors such as alcoholic liver disease, 
smoking, and malnutrition affect the maximum safe dose of 
acetaminophen.  
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(Charles	  Darwin)	  Example	  PBPK	  model2	  
Results 
•  A PBPK model of acetaminophen metabolism was implemented 
using the Mathematica program. 
•  Figure 1 shows good correspondence between the model’s 
predictions (blue) with experimental data6 (red). 
Figure	  1:	  ConcentraDon	  of	  acetaminophen	  in	  the	  venous	  system:	  model	  
predicDon	  in	  blue,	  experimental	  data	  in	  red.	  IniDal	  acetaminophen	  dose:	  
1000	  mg.	  RMSD	  =	  0.0029.	  
Figure	  2:	  Predicted	  concentraDon	  of	  anDoxidant	  GSH	  as	  a	  funcDon	  of	  
acetaminophen	  dose,	  for	  diﬀerent	  subject	  condiDons.	  Liver	  necrosis	  occurs	  
when	  GSH	  is	  depleted	  to	  ~70%	  of	  normal	  (red).	  
Physiologically-­‐based	  
pharmacokineDc	  (PBPK)	  modeling1	  
The block diagram (left) is an example of how a human 
(right) can be modeled: 
•  Organs appear as compartments (blocks) connected by 
blood flow (arrows). 
•  The model is described using mathematics (differential 
equations). 
Pharmacokinetics is divided into several processes: 
•  Absorption: Drugs can enter the body through various 
portals such as intravenous or oral routes. 
•  Distribution: Drugs circulate through the body via blood 
flow, or accumulate in tissue. 
•  Metabolism: Drugs may be changed or broken down into 
other substances. 
•  Elimination: Drugs or their metabolic products are 
eliminated from the body through various routes including 
the kidney (urine), liver, or lungs. 
Acetaminophen	  metabolism,	  detoxiﬁcaDon,	  and	  toxicity4	  
Metabolism:	  Acetaminophen (black in figure) is 
metabolized in the liver into: 
•  Acetaminophen glucuronide (blue) — nontoxic. 
•  Acetaminophen sulfate (blue)  — nontoxic. 
•  NAPQI (N-acetyl-p-benzoquinone imine), catalyzed by 
CYP (cytochrome P450) enzymes (red) — toxic. 
DetoxiﬁcaDon	  
•  NAPQI is rapidly detoxified via combination with GSH 
(glutathione) (purple). 
•  The level of GSH may be reduced due to medical 
conditions or xenobiotics (substances found in the body 
but not expected to be present). 
Toxicity:	  Toxic levels of NAPQI may be caused by: 
•  Overdose  of acetaminophen (more than 10-15 g) 
overwhelming the detoxification process.  
•  Depletion of GSH preventing detoxification of NAPQI 
(possibly caused by alcohol or malnutrition). 
•  Excessive CYP activation producing too much NAPQI 
(possibly caused by smoking or other medications). 
Acetaminophen	  
 … is also known as paracetamol and APAP. 
 … is a common analgesic (pain reliever) and antipyretic (fever 
reducer). 
 … has molecular formula C8H9NO2 (figures at left). 
 … is sold under brand names including Anacin-3, Panadol, and 
Tylenol (figures at right); it may be combined with other ingredients 
such as codeine. 
•  Susceptibility to acetaminophen-induced liver necrosis depends 
on the initial concentration of GSH and metabolic activity. 
•  Figure 2 shows the model’s prediction of concentrations of GSH 
vs. acetaminophen dose for patients under different conditions. 
•  Table 1 lists the acetaminophen dose that depletes GSH 
concentration to 70% of normal under different conditions. 
•  Patients who enter the toxicity region at a lower drug dose are 
more subject to acetaminophen poisoning. 
Clinical	  Signiﬁcance	  in	  U.S.3	  
•  Over 370 million packages of acetaminophen sold in 2008. 
•  Average 44,000+ emergency department visits annually (2000-2007). 
•  Average 33,500+ hospitalizations annually related to overdose (2000-2006).	  
Grant	  No.	  0952013	  
Liver necrosis (cell death) 
occurs when GSH is depleted 
to ~70% of normal levels5. 
CondiDon	   Dose	  (g)	   Notes	   Ref	  
Maximum	  safe	  dosage	   4.00	   Maximum	  safe	  dosage	  should	  be	  no	  greater	  than	  4	  g	  in	  a	  24-­‐hour	  period.	   4	  
Model	  control	   4.22	   Model	  predicts	  dose	  greater	  than	  maximum	  safe	  dosage	  to	  deplete	  GSH	  to	  70%	  
of	  normal.	  
n/a	  
Smoking	   4.26	   Based	  on	  benzothiazole	  exposure	  in	  rats,	  with	  metabolism	  in	  model	  tuned	  to	  
match	  reported	  enzyme	  acBviBes.	  
7	  
Smoking	   1.00	   Based	  on	  benzothiazole	  exposure	  in	  rats,	  with	  metabolism	  in	  model	  tuned	  to	  




0.61	   Malnourishment	  deﬁned	  as	  intake	  of	  protein	  less	  than	  20	  g/day	  for	  at	  least	  one	  
week.	  IniBal	  GSH	  level	  is	  reduced	  to	  75%	  of	  normal.	  
8	  
Alcoholic	  liver	  disease	   2.75	   IniBal	  GSH	  level	  is	  reduced	  to	  91%	  of	  normal	  (mitochondrial	  GSH	  is	  depleted	  by	  
45-­‐60%;	  mitochondrial	  GSH	  makes	  up	  10-­‐15%	  of	  total	  cellular	  GSH).	  
9	  
Table	  1:	  Predicted	  acetaminophen	  dose	  that	  depletes	  GSH	  level	  to	  70%	  of	  
normal	  for	  diﬀerent	  paDent	  condiDons.	  
